GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study
Inflammatory Bowel Diseases · 21.08.2026
DOI: 10.1093/ibd/izag167 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 21.08.2026. Verfasst von Budoor Alqinai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Department of Medicine, West Virginia University, Morgantown, WV, United States. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Background
Ulcerative colitis (UC) remains associated with significant morbidity despite therapeutic advances. The impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on UC disease activity is not well defined.
Methods
We performed a retrospective cohort study using electronic health records from a single tertiary academic health system (2022-2024). Adults with UC initiating liraglutide or semaglutide for metabolic indications and maintained on therapy ≥ 12 weeks were included. A 1:1 matched cohort of UC patients not receiving GLP-1 RAs served as controls. The primary outcome was symptomatic remission at 12 weeks (partial Mayo ≤ 2 with rectal bleeding subscore 0). Multivariable logistic regression assessed adjusted odds of remission.
Results
A total of 150 GLP-1 RA patients were matched to 150 controls with comparable baseline characteristics. GLP-1 RA use was associated with higher remission rates at 4 weeks (34.7% vs 15.3%, P = .001), 8 weeks (54.7% vs 18.0%, P < .001), and 12 weeks (66.7% vs 25.3%, P < .001). Mean partial Mayo scores improved from 5.8 at baseline to 2.1 at 12 weeks in the GLP-1 RA group vs 4.6 in controls (P < .01). GLP-1 RA use remained independently associated with remission (adjusted OR 5.90, 95% CI 3.52-9.86; P < .001). Weight loss was not associated with remission. Semaglutide demonstrated higher remission rates than liraglutide (72.5% vs 60%; OR 1.77, P = .04). Endoscopic outcomes in a subset showed higher remission (58% vs 38%) and improvement (69% vs 47%).
Conclusion
GLP-1 RA therapy was associated with significantly improved UC disease activity and higher remission rates compared to matched controls, with a modest advantage observed for semaglutide. These findings support a potential adjunctive role for GLP-1 RAs in UC, particularly in patients with metabolic comorbidities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Internal Medicine, Department of Medicine, West Virginia University, Morgantown, WV, United States.
- Department of Medicine, Division of Gastroenterology and Hepatology, West Virginia University, Morgantown, WV, United States.
ORCID-Profile: Budoor Alqinai
Zitieren
APA
Alqinai, B., Gayam, S., & Hadam-Veverka, J. (2026). GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag167
Vancouver
Alqinai B, Gayam S, Hadam-Veverka J. GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag167
BibTeX
@article{Alqinai2026,
author = {Alqinai, Budoor and Gayam, Swapna and Hadam-Veverka, Jennifer},
title = {GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag167}
}
EUVIMED